Smith+Nephew’s TESSA™ Spatial Surgery System granted De Novo classification by the FDA sparking a generational leap in Sports Medicine for personalized planning and procedural innovation
Smith+Nephew said the FDA granted De Novo classification for its TESSA Spatial Surgery System, an intra-articular orthopedic stereotaxic navigation device for ACL reconstruction. The system uses pre-op MR/CT scans and cloud AI on AWS, overlaid on live 4K arthroscopic video. Commercial launch is planned for Q3 2026, with broader deployment in 2027.
How this was made
The 30-second read
Why it matters
The FDA De Novo classification creates a regulatory reference point for intra-articular orthopedic stereotaxic navigation instruments and supports commercialization planning for sports medicine applications starting with ACL reconstruction.
Market read
Regulatory clearance plus a stated launch timeline (Q3 2026) can re-rate expectations for Smith+Nephew’s digital sports medicine growth, but the magnitude depends on adoption and reimbursement.
What to watch
Key gating items are reimbursement status, surgeon workflow integration, evidence generation beyond ACL reconstruction, and competitive positioning in navigation/AR surgical guidance.
Background
Smith+Nephew’s TESSA uses pre-op MR/CT scans to create patient-specific 3D models, then overlays them onto live arthroscopic video with real-time navigation.
Ticker impact
Smith+Nephew received FDA De Novo classification for its TESSA spatial surgery system, enabling a new device category for intra-articular orthopedic navigation.
Near-term upside bias on clearance credibility, with follow-through tied to Q3 2026 commercialization progress and adoption.
The article discloses a primary regulatory milestone (De Novo) plus stated commercialization timing (Q3 2026) and first indication (ACL reconstruction), which are actionable for positioning. However, it provides no sales, clinical outcomes, or competitive benchmarks to quantify magnitude.
Market effects
Supports the broader shift toward AI-enabled, navigation-assisted orthopedic procedures and may raise investor expectations for similar stereotaxic navigation entrants.
Primarily US regulatory catalyst, but likely impacts global medtech sentiment given Smith+Nephew’s worldwide footprint.
US FDA clearance can influence international adoption pathways and future regulatory submissions for related indications.
Counterpoint
De Novo classification does not guarantee clinical adoption or reimbursement; without outcome data and payer coverage, near-term financial impact may be limited.
Key entities
- companySmith+Nephew
Medical technology company granted FDA De Novo classification for the TESSA Spatial Surgery System.
- productTESSA Spatial Surgery System
Tracking Enabled Spatial Surgery Assistant using AI-generated 3D models and AR overlay for intraoperative navigation.
- regulatorU.S. Food & Drug Administration (FDA)
Granted De Novo classification for the device, establishing a new regulatory category.
- technology_providerAmazon Web Services (AWS)
Cloud platform referenced as the environment for running the system’s deep-learning algorithms.
- technology_providerNVIDIA
AI infrastructure referenced as powering the TESSA system.
